 Business Update
May 24, 2024
The Duckhorn Portfolio, Inc. (NYSE: NAPA), a leading producer of fine wines, has recently announced its enhanced distribution relationships with Republic National Distributing Company (RNDC) and Breakthru Beverage Group (BBG). This strategic move comes as a result of the Company s thorough evaluation of its wholesal...
|
Announcement
May 24, 2024
Adlai Nortye Ltd. Presents Encouraging Data on AN0025 in Combination with Definitive Chemoradiotherapy for Esophageal CancerAdlai Nortye Ltd., a clinical-stage biotechnology company, is set to present promising preliminary data at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting in Chicago. Th...
|
Business Update
May 24, 2024
Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company focused on developing nucleic acid-based therapeutics, has recently received a delisting determination notice from The Nasdaq Stock Market LLC (Nasdaq). The notice was issued due to the company s failure to file its Form 10-K for the year ended Dec...
|
|
 Business Update
May 24, 2024
TriSalus Life Sciences Initiates Exchange Offer and Consent Solicitation for Warrants DENVER - TriSalus Life Sciences Inc. (Nasdaq: TLSI), a prominent oncology company known for its innovative delivery technology integrated with immunotherapy to treat liver and pancreatic tumors, has officially launched an exchange ...
 Clinical Study
May 24, 2024
Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a rare and life-threatening disease characterized by the accumulation of amyloid fibrils in the heart, has seen limited therapeutic options until recently. However, a groundbreaking study, known as ATTRibute-CM, has demonstrated the potential of Acoramidis, a novel the...
|
|
Our most Popular Articles
|
Clinical Study
September 4, 2024
In a promising development for multiple myeloma treatment, ALX Oncology has announced the dosing of the first patients in its UMBRELLA study, a randomized Phase 1/2 clinical trial evaluating the efficacy of Evorpacept, an investigational CD47-blocking therapeutic, in combination with Sarclisa, Sanofi s approved CD38...
|
Contract
March 21, 2024
In a remarkable turn of events, ABM Industries Inc, an industry leader in facility management solutions, is playing a crucial role in supporting the growth of the U.S. semiconductor manufacturing sector. This is largely due to the enactment of the CHIPS and Science Act of 2022, which prompted leading semiconductor c...
|
Stocks on the Move
July 10, 2024
Mohawk Industries Inc, a leading company in the furniture and fixtures industry, has been attracting attention with its recent stock performance. Over the past week, Mohawk Industries Inc s share price has outperformed competitors, leading to speculation about the underlying factors driving this trend. This article ...
|
|
|
Company News
|
Announcement
May 24, 2024
Adlai Nortye Ltd. Presents Encouraging Data on AN0025 in Combination with Definitive Chemoradiotherapy for Esophageal CancerAdlai Nortye Ltd., a clinical-stage biotechnology company, is set to present promising preliminary data at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting in Chicago. Th...
|
Business Update
May 24, 2024
Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company focused on developing nucleic acid-based therapeutics, has recently received a delisting determination notice from The Nasdaq Stock Market LLC (Nasdaq). The notice was issued due to the company s failure to file its Form 10-K for the year ended Dec...
|
Business Update
May 24, 2024
Legend Biotech Corporation (NASDAQ: LEGN), a leading global player in the field of cell therapy, recently made groundbreaking announcements regarding their CAR-T cell therapy, CARVYKTI (ciltacabtagene autoleucel, or cilta-cel). This therapy aims to revolutionize the treatment landscape for patients with relapsed and...
|
|
|
Company News
 Business Update
May 24, 2024
|
Company News
 Business Update
May 24, 2024
|
Company News
 Business Update
May 24, 2024
|
More Company News
|
Business Update
May 24, 2024
|
Business Update
May 24, 2024
|
Business Update
May 24, 2024
|
Business Update
May 24, 2024
|
Business Update
May 24, 2024
|
Business Update
May 24, 2024
|
Business Update
May 24, 2024
|
Business Update
May 24, 2024
|
Product Service News
Cutting-Edge Oncological Advances: HUTCHMED's Groundbreaking Presentations at ASCO 2024 and Significant Developments in AML and NSCLC Treatments'
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting'
HONG KONG, SHANGHAI, China, and FLORHAM PARK, N.J., May 23, 2024 - HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13), a leading biopharmaceutical company dedicated to the discovery and development of innovative oncology and immunology therapies, is poised to make a significant impact at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. The event, scheduled to take place from May 31 to June 4, 2024, both in Chicago, IL and online, will showcase new and updated data stemming from several of HUTCHMED's pioneering cancer treatment compounds.
The ASCO Annual Meeting is a premier event that convenes the brightest minds in oncology to share therapeutic advancements and clinical research that have the potential to redefine patient care. HUTCHMED's presentations will include updates on various compounds that have shown promising efficacy and safety profiles in treating multiple cancer forms. These developments align with HUTCHMED's mission to address significant unmet medical needs and improve patient outcomes through cutting-edge science.
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for AML Patients in China'
In a series of strategic milestones, HUTCHMED has also initiated the RAPHAEL registrational Phase III clinical trial of HMPL-306 in China, targeting patients with relapsed or refractory acute myeloid leukemia (AML) harboring IDH1 and/or IDH2 mutations. The trial commenced on May 14, 2024, with the first patient receiving their initial dose on May 11, 2024. HMPL-306, a highly selective, orally available inhibitor of IDH1 and IDH2, represents a significant scientific breakthrough with the potential to transform treatment paradigms for patients suffering from this aggressive and often intractable form of leukemia.
The initiation of the RAPHAEL trial underscores HUTCHMED’s commitment to expediting the clinical development of novel therapeutic options for hematological malignancies, addressing critical and unmet medical needs within the oncology domain.
Savolitinib's sNDA Accepted in China for NSCLC Treatment'
Furthermore, HUTCHMED has achieved another notable advancement with its targeted therapy savolitinib, as the supplementary New Drug Application (sNDA) has been accepted in China for the treatment of treatment-naïve or previously treated patients with locally advanced or metastatic MET exon 14 skipping non-small cell lung cancer (NSCLC).
As underscored by an oral presentation at the European Lung Cancer Congress 2024, Phase IIIb data revealed a median progression-free survival (PFS) of 13.7 months and a median overall survival (OS) that has yet to be reached in treatment-naïve patients receiving savolitinib. These encouraging results reaffirm savolitinib's therapeutic potential and set it apart as a promising option for managing MET exon 14 skipping alterations in NSCLC, a genetic subset renowned for its poor prognosis and limited treatment options.
Conclusion'
HUTCHMED's accomplishments and forthcoming presentations signal a momentous leap forward in cancer research and treatment. With their innovative compounds and rigorous clinical trials, they continue to pave the way for groundbreaking therapies that may significantly enhance survival and quality of life for cancer patients globally. As ASCO 2024 approaches, the oncology community eagerly anticipates the detailed findings and future potential of HUTCHMED's novel treatments.
HUTCHMED's cutting-edge developments exemplify a relentless pursuit of scientific innovation and therapeutic excellence, hallmarks that fortify their leading position in the global oncology landscape.
May 24, 2024
|
Business Update
May 24, 2024
|
|
|
|
Related News
|
Clinical Study
|
|
Clinical Study
|
|
Stocks
|
Business Update
|
|
Business Update
|
|
Business Update
|
|
|
|
Business News
|
 Business Update
TriSalus Life Sciences Initiates Exchange Offer and Consent Solicitation for Warrants DENVER - TriSalus Life Sciences Inc. (Nasdaq: TLSI), a prominent oncology company known for its innovative delivery technology integrated with immunotherapy to treat liver and pancreatic tumors, has officially launched an exchange ...
|
|
Clinical Study
Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a rare and life-threatening disease characterized by the accumulation of amyloid fibrils in the heart, has seen limited therapeutic options until recently. However, a groundbreaking study, known as ATTRibute-CM, has demonstrated the potential of Acoramidis, a novel the...
|
|
Announcement
Revenue and Earnings See Significant Growth, Highlighting Strong Fiscal Year Syntec Optics Holdings, Inc. (Nasdaq: OPTX), a leader in precision optics solutions, released its financial results for the fourth quarter of 2023, the full year 2023, and the first quarter of 2024. The company reported notable improvements...
|
 Clinical Study
Bio-Path Holdings Reports Promising Developments in Acute Myeloid Leukemia Therapies at Upcoming EHA Congress: Prexigebersen Interim Success and BP1002 Milestone Bio-Path Holdings Reports Promising Developments in Acute Myeloid Leukemia Therapies at Upcoming EHA Congress: Prexigebersen Interim Success and BP1002 Mil...
|
 Business Update
The Duckhorn Portfolio, Inc. (NYSE: NAPA), a leading producer of fine wines, has recently announced its enhanced distribution relationships with Republic National Distributing Company (RNDC) and Breakthru Beverage Group (BBG). This strategic move comes as a result of the Company s thorough evaluation of its wholesal...
|
Our Most Popular Articles
|
|
Clinical Study
In a promising development for multiple myeloma treatment, ALX Oncology has announced the dosing of the first patients in its UMBRELLA study, a randomized Phase 1/2 clinical trial evaluating the efficacy of Evorpacept, an investigational CD47-blocking therapeutic, in combination with Sarclisa, Sanofi s approved CD38...
|
 Contract
In a remarkable turn of events, ABM Industries Inc, an industry leader in facility management solutions, is playing a crucial role in supporting the growth of the U.S. semiconductor manufacturing sector. This is largely due to the enactment of the CHIPS and Science Act of 2022, which prompted leading semiconductor c...
|
 Stocks on the Move
Mohawk Industries Inc, a leading company in the furniture and fixtures industry, has been attracting attention with its recent stock performance. Over the past week, Mohawk Industries Inc s share price has outperformed competitors, leading to speculation about the underlying factors driving this trend. This article ...
|
More News
|
 Announcement
Adlai Nortye Ltd. Presents Encouraging Data on AN0025 in Combination with Definitive Chemoradiotherapy for Esophageal CancerAdlai Nortye Ltd., a clinical-stage biotechnology company, is set to present promising preliminary data at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting in Chicago. Th...
|
 Business Update
Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company focused on developing nucleic acid-based therapeutics, has recently received a delisting determination notice from The Nasdaq Stock Market LLC (Nasdaq). The notice was issued due to the company s failure to file its Form 10-K for the year ended Dec...
|
 Business Update
Legend Biotech Corporation (NASDAQ: LEGN), a leading global player in the field of cell therapy, recently made groundbreaking announcements regarding their CAR-T cell therapy, CARVYKTI (ciltacabtagene autoleucel, or cilta-cel). This therapy aims to revolutionize the treatment landscape for patients with relapsed and...
|
|
Business Update
United States Steel Opens Direct Reduced-Grade Pellet Production Facility in MinnesotaUnited States Steel (NYSE: X) has announced the successful launch and operational readiness of its direct reduced-grade pellet production facility at the Minnesota Ore Operations-Keetac Plant in Keewatin, Minnesota. The company has...
|
|
Business Update
Vancouver, British Columbia Pan American Silver Corp. (NYSE: PAAS) (TSX: PAAS), a leading player in the global mining sector, has released its much-anticipated 2023 Sustainability Report, alongside an annual update on its exploration activities. The dual announcements highlight the company’s robust performance ...
|
|
Business Update
Klaviyo, the company known for powering smarter digital relationships, has announced that their Chief Financial Officer, Amanda Whalen, will be participating in a fireside chat at the upcoming William Blair Growth Stock Conference. The conference is scheduled to take place on Thursday, June 6, 2024, at 9:00 a.m. ET ...
|
 Business Update
Dallas-based technology company Enhabit, Inc. (NYSE: EHAB) has recently unveiled additional details regarding its robust strategic review process. The company aims to enhance its business operations and drive accelerated growth, as outlined in the preliminary proxy materials filed with the Securities and Exchange Co...
|
 Business Update
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual MeetingLEXINGTON, Mass. - Agenus Inc. (Agenus), a leading developer of immunological agents for cancer treatment, has announced that a novel analysis from the Phase 1b trial of botensilimab in combination with balstilimab (BOT...
|
 Business Update
Bicycle Therapeutics, a leading pharmaceutical company specializing in the development of innovative therapeutics, has recently shared exciting updates regarding their Phase 1/2 clinical trials. The company s proprietary bicyclic peptide technology has demonstrated impressive pharmacokinetic (PK) and safety data for...
|
 Business Update
Secret Creek Fish Passage Project Nets Granite $48 Million Contract in Snohomish County, WashingtonWatsonville, Calif. - Granite (NYSE:GVA) has recently been awarded a $48 million contract by the Washington State Department of Transportation (WSDOT) to replace two existing fish barrier culvert crossings with three n...
|
 Business Update
Oklo Partners with Wyoming Hyperscale to Deliver 100 Megawatts to its Data CentersSANTA CLARA, Calif. Oklo Inc. (NYSE: OKLO), a pioneer in the field of fast fission clean power technology and nuclear fuel recycling, has recently announced a groundbreaking collaboration with Wyoming Hyperscale to provide 100 megawa...
|
 Business Update
Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial in Metastatic Pancreatic CancerBOSTON Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company dedicated to advancing novel therapies for cancer patients, has unveiled promising initial interim safety and efficacy results from its ongoi...
|
 Business Update
Barnes & Noble Education, Inc. (NYSE: BNED) has recently released its preliminary, unaudited financial results for the twelve months ending April 27, 2024. As a leading solutions provider for the education industry, BNED has demonstrated its resilience and ability to adapt to the evolving landscape of education. Despite the challenges posed by the COVID-19 pandemic, BNED has managed to achieve impressive fiscal year 2024 results, showcasing its commitment to student success and growth within the sector.Consolidated Revenue Growth:The preliminary unaudited financial results for fiscal year 2024 highlight BNED s robust growth. The company reported a consolidated GAAP revenue of approximately $1,567 million for the fiscal year, representing a modest increase from $1,543 million in the prior year period. This revenue growth is commendable considering the unprecedented disruptions faced by educational institutions due to the pandemic.
|
 Business Update
Guardant Health s Shield Blood Test Receives Strong FDA Committee Recommendation for Colorectal Cancer ScreeningPALO ALTO, Calif. - In a groundbreaking development for cancer screening, Guardant Health, a leading precision oncology company, has announced that the Molecular and Clinical Genetics Panel of the U.S. Foo...
|
 Product Service News
Cutting-Edge Oncological Advances: HUTCHMED's Groundbreaking Presentations at ASCO 2024 and Significant Developments in AML and NSCLC Treatments'
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting'
HONG KONG, SHANGHAI, China, and FLORHAM PARK, N.J., May 23, 2024 - HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13), a leading biopharmaceutical company dedicated to the discovery and development of innovative oncology and immunology therapies, is poised to make a significant impact at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. The event, scheduled to take place from May 31 to June 4, 2024, both in Chicago, IL and online, will showcase new and updated data stemming from several of HUTCHMED's pioneering cancer treatment compounds.
The ASCO Annual Meeting is a premier event that convenes the brightest minds in oncology to share therapeutic advancements and clinical research that have the potential to redefine patient care. HUTCHMED's presentations will include updates on various compounds that have shown promising efficacy and safety profiles in treating multiple cancer forms. These developments align with HUTCHMED's mission to address significant unmet medical needs and improve patient outcomes through cutting-edge science.
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for AML Patients in China'
In a series of strategic milestones, HUTCHMED has also initiated the RAPHAEL registrational Phase III clinical trial of HMPL-306 in China, targeting patients with relapsed or refractory acute myeloid leukemia (AML) harboring IDH1 and/or IDH2 mutations. The trial commenced on May 14, 2024, with the first patient receiving their initial dose on May 11, 2024. HMPL-306, a highly selective, orally available inhibitor of IDH1 and IDH2, represents a significant scientific breakthrough with the potential to transform treatment paradigms for patients suffering from this aggressive and often intractable form of leukemia.
The initiation of the RAPHAEL trial underscores HUTCHMED’s commitment to expediting the clinical development of novel therapeutic options for hematological malignancies, addressing critical and unmet medical needs within the oncology domain.
Savolitinib's sNDA Accepted in China for NSCLC Treatment'
Furthermore, HUTCHMED has achieved another notable advancement with its targeted therapy savolitinib, as the supplementary New Drug Application (sNDA) has been accepted in China for the treatment of treatment-naïve or previously treated patients with locally advanced or metastatic MET exon 14 skipping non-small cell lung cancer (NSCLC).
As underscored by an oral presentation at the European Lung Cancer Congress 2024, Phase IIIb data revealed a median progression-free survival (PFS) of 13.7 months and a median overall survival (OS) that has yet to be reached in treatment-naïve patients receiving savolitinib. These encouraging results reaffirm savolitinib's therapeutic potential and set it apart as a promising option for managing MET exon 14 skipping alterations in NSCLC, a genetic subset renowned for its poor prognosis and limited treatment options.
Conclusion'
HUTCHMED's accomplishments and forthcoming presentations signal a momentous leap forward in cancer research and treatment. With their innovative compounds and rigorous clinical trials, they continue to pave the way for groundbreaking therapies that may significantly enhance survival and quality of life for cancer patients globally. As ASCO 2024 approaches, the oncology community eagerly anticipates the detailed findings and future potential of HUTCHMED's novel treatments.
HUTCHMED's cutting-edge developments exemplify a relentless pursuit of scientific innovation and therapeutic excellence, hallmarks that fortify their leading position in the global oncology landscape.
Cutting-Edge Oncological Advances: HUTCHMED s Groundbreaking Presentations at ASCO 2024 and Significant Developments in AML and NSCLC Treatments HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting HONG KONG, SHANGHAI, China, and FLORHAM PARK, N.J., May 23, 2024 - HUTCHMED (China) Limited (Nasdaq/AIM:...
|
|
Business Update
Barnes & Noble Education s Fiscal Year 2024: A Prelude to Transformation Barnes & Noble Education, Inc. (NYSE: BNED), a fixture in the education solutions sector, has announced its preliminary, unaudited financial results for the twelve months ending April 27, 2024. The recently reported numbers reflect an incremen...
|
|
|
|
|
